Its not classified as a diuretic the way SGLT2 inhibitors or loop diuretics are, but the combination of mobilized water from fat loss, increased fluid intake to manage nausea, and modest renal effects adds up
Bottom Line Cagrilintide peptide is used for obesity and metabolic research because it targets the amylin pathway, a satiety and appetite-regulation system that complements GLP-1 biology
Neurocognitive peptides specifically target the brain and nervous system to enhance functions such as memory, focus, mood regulation, and neuroprotection
31, 2025 (GLOBE NEWSWIRE) -- Truvetas groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open , offering critical insights into GLP-1 discontinuation and reinitiation rates, and the roles income, adverse events, and weight changes may play